286 studies found for:    PLG
Show Display Options
Rank Status Study
1 Completed In Vivo Angiostatin Generation Using Tissue Plasminogen Activator and Captopril in Treating Patients With Progressive Metastatic Cancer
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: recombinant tissue plasminogen activator;   Drug: captopril
2 Recruiting Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients
Condition: Ligneous Conjunctivitis
Intervention: Biological: Human Plasminogen
3 Active, not recruiting A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion
Condition: Acute Peripheral Arterial Occlusion
Interventions: Biological: Plasmin;   Biological: Plasminogen Activator;   Other: Placebo
4 Completed Comparison of Different TRansesophageal Echocardiography Guided thrOmbolytic Regimens for prosthetIc vAlve Thrombosis
Condition: Prosthetic Valve Thrombosis
Interventions: Drug: Streptokinase;   Drug: Tissue plasminogen activator;   Drug: Tissue Plasminogen Activator
5 Completed Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults
Condition: HIV Infections
Interventions: Biological: Clade B gag DNA/PLG and env DNA/PLG Microparticles;   Biological: Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant
6 Completed Low Dosage of rt-PA in the Treatment of Pulmonary Thromboembolism in China
Conditions: Pulmonary Embolism;   Thromboembolism
Intervention: Drug: rt-PA
7 Recruiting Urine-plasminogen as a Predictor for Development Of Preeclampsia in Pregnant Women With Type 1 Diabetes Mellitus
Conditions: Preeclampsia;   Type 1 Diabetes
Intervention:
8 Unknown  Intraventricular Tissue Plasminogen Activator (tPA) in the Management of Aneurysmal Subarachnoid Hemorrhage
Conditions: Aneurysmal Subarachnoid Hemorrhage;   Intraventricular Hemorrhage
Interventions: Drug: Tissue Plasminogen Activator;   Drug: Placebo
9 Completed Heavy Metals, Angiogenesis Factors and Osteopontin in Coronary Artery Disease (CAD)
Conditions: Ischemic Heart Disease;   Coronary Artery Disease;   Heavy Metal Toxicity
Intervention:
10 Unknown  Study to Assess the Safety and Efficacy of THR-18 When Administered to Patients Suffering Acute Ischemic Stroke and Treated With Tissue Plasminogen Activator (tPA)
Condition: Acute Ischemic Stroke
Interventions: Drug: THR-18;   Drug: Placebo
11 Terminated Evaluation of the Role of Intravitreal Tissue Plasminogen Activator in Treatment of Refractory Diabetic Macular Edema
Condition: Diabetic Macular Edema
Intervention: Drug: Tissue Plasminogen Activator,bevacizumab ,follow up
12 Completed
Has Results
Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke
Conditions: Cerebral Infarction;   Brain Ischemia
Intervention: Drug: Alteplase
13 Terminated Safety and Effectiveness of tPA in Intra-abdominal Abscesses
Condition: Abscess
Interventions: Drug: Tissue Plasminogen Activator;   Other: Normal Saline
14 Unknown  Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)
Condition: Stroke
Interventions: Drug: tenecteplase;   Drug: tissue plasminogen activator, tPA
15 Recruiting Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)
Condition: Pleural Empyema
Interventions: Drug: tPA;   Drug: DNase;   Other: Placebo
16 Enrolling by invitation Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-Critical Coronary Artery Disease
Condition: Coronary Artery Disease
Intervention: Drug: Bradykinin
17 Completed Safety Study of a Recombinant Human Plasminogen Activator to Treat Acute Ischemic Stroke.
Condition: Cerebrovascular Accident
Intervention: Genetic: Recombinant Human Plasminogen Activator (HTUPA)
18 Completed A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)
Condition: Acute Ischemic Stroke
Intervention: Drug: YM872 (zonampanel), t-PA (alteplase)
19 Recruiting Low Dose Prolonged Infusion of Tissue Type Plasminogen Activator Therapy in Massive Pulmonary Embolism
Condition: Pulmonary Embolism
Intervention: Drug: 25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours
20 Recruiting Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke
Condition: Acute Ischemic Stroke
Interventions: Device: Transcranial ultrasound as an adjunctive therapy to tPA;   Drug: Standard of care tPA therapy for acute ischemic stroke

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years